Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial

Pediatric Blood and Cancer

Volumn 63, Issue 1, 2016, Pages 98-104

  McGann, Patrick T ^a   Tshilolo, Léon ^b   Santos, Brigida ^c   Tomlinson, George A ^d   Stuber, Susan ^a   Latham, Teresa ^a   Aygun, Banu ^e   Obaro, Stephen K ^f   Olupot Olupot, Peter ^g   Williams, Thomas N ^h,i   Odame, Isaac ^j   Ware, Russell E ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b Centre Hospitalier Monkole   (Congo)

^c Hospital Pediatrico David Bernardino   (Angola)

^d UNIVERSITY OF TORONTO   (Canada)

^e Northwell Health   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g Mbale Regional Hospital Clinical Research Unit   (Uganda)

^h KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

^j HOSPITAL FOR SICK CHILDREN   (Canada)

more..

Author keywords

Africa; Hydroxyurea; Sickle cell anemia

Indexed keywords

HYDROXYUREA; PLACEBO; UNCLASSIFIED DRUG;

AFRICA SOUTH OF THE SAHARA; ANEMIA; ARTICLE; BLOOD TOXICITY; CHILD; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG SAFETY; FEASIBILITY STUDY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETICULOCYTOPENIA; SICKLE CELL ANEMIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; ANEMIA, SICKLE CELL; CLINICAL TRIAL; INFANT; PRESCHOOL CHILD; PROSPECTIVE STUDY;

AFRICA SOUTH OF THE SAHARA; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; HUMANS; HYDROXYUREA; INFANT; PROSPECTIVE STUDIES;

EID: 84983095657     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25705     Document Type: Article

References (42)

1. Weatherall D, Hofman K, Rogers G, Ruffin J, Hrynkow S. A case for developing North-South partnerships for research in sickle cell disease. Blood 2005; 105:921-923.
2. World Health Organization: Regional Office for Africa. Sickle-cell disease: A strategy for the WHO African Region. June 2010.
3. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, Temperley WH, Williams TN, Weatherall DJ, Hay SI. Global epidemiology of sickle haemoglobin in neonates: A contemporary geostatistical model-based map and population estimates. Lancet 2013; 381:142-151.
4. McGann PT. Sickle cell anemia: An underappreciated and unaddressed contributor to global childhood mortality. J Pediatr 2014; 165:18-22.
5. Telfer P, Coen P, Chakravorty S, Wilkey O, Evans J, Newell H, Smalling B, Stephens A, Rogers D, Kirkham F. Clinical outcomes in children with sickle cell disease living in England: A neonatal cohort in East London. Haematologica 2007; 92:905-912.
6. Quinn CT, Rogers ZR, McCavitt TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115:3447-3452.
7. Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA. The risks and benefits of long-term hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010; 85:403-408.
8. Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, Childs RW, Rodgers GP, Powell JD, Tisdale JF. Allogeneic hematopoieitic stem-cell transplantation for sickle cell disease. N Engl J Med 2009; 361:2309-2317.
9. Wang WC, Dwan K. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database Syst Rev 2013; 11:CD003146.
10. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: A neglected cause of early childhood mortality. Am J Prev Med 2010; 41:S398-S405.
11. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: An increasing global health problem. Bull World Health Organ 2001; 79:704-712.
12. Williams TN, Uyoga S, Macharia A, Ndila C, McAuley CF, Opi DH, Makain J, Ndiriru MN, Sharif SK, Marsh K, Berkley JA, Scott JA. Bacteraemia in Kenyan children with sickle-cell anaemia: A retrospective cohort and case-control study. Lancet 2009; 374:1364-1370.
13. Odame I. Developing a global agenda for sickle cell disease: Report of an international symposium and workshop in Cotonou, Republic of Benin. Am J Prev Med 2010; 38:S571-S575.
14. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: Modelling based on demographics, excess mortality, and interventions. PLoS Med 2013; 10:e1001484.
15. Rahimy MC, Gangbo A, Ahouignan G, Alihonou E. Newborn screening for sickle cell disease in the Republic of Benin. J Clin Pathol 2009; 62:46-48.
16. Tshilolo L, Aissi LM, Lukusa D, Kinsiama C, Wembonyama S, Gulbis B, Vertongen F. Neonatal screening for sickle cell anaemia in the Democratic Republic of the Congo: Experience from a pioneer project on 31 204 newborns. J Clin Pathol 2009; 62:35-38.
17. McGann PT, Ferris MG, Ramamurthy U, Santos B, de Oliveira V, Bernardino L, Ware RE. A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola. Am J Hematol 2013; 88:984-989.
18. Chakravorty S, Williams TN. Sickle cell disease: A neglected chronic disease of increasing global importance. Arch Dis Child 2015; 100:48-53.
19. McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: What have we learned and what questions still remain? Curr Opin Hematol 2011; 18:158-165.
20. Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smelzer MP, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 2011; 118:4885-4991.
21. Heeney MH, Whorton MR, Howard TA, Johnson CA, Ware RE. Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol 2004; 26:179-184.
22. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010; 115:5300-5311.
23. Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999; 94:1550-1554.
24. Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004; 103:2039-2045.
25. Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377:1663-1672.
26. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 2001; 139:790-796.
27. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332:1317-1322.
28. Steinberg MH, McCarthy WF, Castro, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010; 85:403-408.
29. Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle-cell syndromes: Results of a 17-year, single center trial (LaSHS). Blood 2010; 115:2354-2363.
30. Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS. The effect of hydroxycarbamide therapy on survival of children with sickle cell disease. Br J Haematol 2013; 16:852-860.
31. Yawn BP, Buchanan GR, Afenyi-Annan AN. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033-1048.
32. Obaro SK. Hydroxyurea for sickle-cell anaemia in Africa; mind the gap. Lancet Global Health 2015; 3:e124-e125.
33. Odame I. Concerted global effort to combat sickle cell disease: The first global congress on sickle cell disease in Accra, Ghana. J Prev Med 2011; 41:S417-S421.
34. Williams TN, Obaro SK. Sickle cell disease and morbidity: A tale with two tails. Trends Parasitol 2011; 27:315-320.
35. WHO Model List of Essential Medicines for Children, 4th List. April 2013, Geneva, Switzerland. http://www.who.int/medicines/publications/essentialmedicines/4th_EMLc_FINAL_web_8Jul13.pdf.
36. Bafeta A, Dechartres A, Trinquart L, Yavchitz A, Boutron I, Ravaud P. Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: Meta-epidemiological study. BMJ 2012; 344:e813.
37. Sadarangani M, Makani J, Komba AN, Alala-Agbo T, Newton CR, Marsh K, Williams TN. An observational study of children with sickle cell disease in Kilifi, Kenya. Br J Haematol 2009; 146:675-682.
38. Simon R. Optimal Two-Stage Designs for Phase II Clinical Trials. Control Clin Trials 1989; 10:1-10.
39. Morisky DE, Ang A, Krousel-Wood M, Ward H. Predictive validity of a medication adherence measure for hypertension control. J Clin Hypertens 2008; 10:348-354.
40. Thornburg CD, Calatroni A, Telen M, Kemper AR. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr 2010; 156:415-419.
41. WHO 2012 Verbal Autopsy Instrument. World Health Organization 2012; Geneva, Switzerland. http://www.who.int/healthinfo/statistics/WHO_VA_2012_RC1_Instrument.pdf.
42. Amendah DD, Mukamah G, Komba, Ndila C, Williams TN. Routine paediatric sickle cell disease (SCD) outpatient care in a rural Kenyan hospital: Utilization and costs. PLoS One 2013; 8:e61130.